tbuckley/cabot-search huggingface dataset:
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Authors: Degao Chen, Xiaomei Zhang, Zhongjun Li, Bo Zhu
Journal: Theranostics (2020)

Macrophages phagocytize pathogens to initiate innate immunity and products from the tumor microenvironment (TME) to mediate tumor immunity. The loss of tumor-associated macrophage (TAM)-mediated immune responses results in immune suppression. To reverse this immune disorder, the regulatory mechanism of TAMs in the TME needs to be clarified. Immune molecules (cytokines and chemokines) from TAMs and the TME have been widely accepted as mutual mediators of signal transduction in the past few decades. Recently, researchers have tried to seek the intrinsic mechanism of TAM phenotypic and functional changes through metabolic connections. Numerous metabolites derived from the TME have been identified that induce the cell-cell crosstalk with TAMs. The bulk tumor cells, immune cells, and stromal cells produce metabolites in the TME that are involved in the metabolic regulation of TAMs. Meanwhile, some products from TAMs regulate the biological functions of the tumor as well. Here, we review the recent reports demonstrating the metabolic regulation between TME and TAMs.
<i>RPS15</i> and <i>TP53</i> Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model
Authors: Catherine Gutierrez, Tamara Ouspenskaia, Doris Fu, Peyton Waddicor, Anat Biran, Aviv Liani, Gregory Lazarian, Elisa Ten Hacken, Elizabeth Witten, Fara Faye Regis, Heather Joyal, Leah Billington, Fabienne Lucas, Mei Zheng, Blake Tye, Maria Hernandez-Sanchez, Miguel Quijada Álamo, Shuqiang Li, Binyamin A. Knisbacher, Ziao Lin, Aziz Al'Khafaji, Lili Wang, Kenneth J. Livak, Donna S. Neuberg, Florence Cymbalista, Gad Getz, Stirling Churchman, Ruben D. Carrasco, Sichen Shao, Aviv Regev, Catherine J. Wu
Journal: Blood (2020)
Diagnosis of idiopathic acute pancreatitis: the simpler, the better?
Authors: Babu P. Mohan
Journal: Endoscopy (2020)

Acute pancreatitis continues to be one of the most common gastrointestinal (GI) conditions requiring hospitalization. The term "idiopathic acute pancreatitis" (IAP) is used when the most common causes of acute pancreatitis, like alcohol and gallstones, have been ruled out, with there also being no discernible etiology after extensive evaluation of patient history, physical examination, laboratory tests, and conventional imaging studies [1] [2]. Transabdominal ultrasound and computed tomography (CT) are the usual initial imaging modalities and are indicated after causes such as drugs, infections, genetic mutations, and metabolic disorders, such as hypercalcemia and hypertriglyceridemia, have been ruled out. A second ultrasound scan sometimes finds a biliary cause, in around 20 % of patients diagnosed as IAP, if the first one was unrevealing [3].
Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma
Authors: Armin Ghobadi, Michael P. Rettig, Amanda F Cashen, Leah Gehrs, Stephanie Christ, Neha Mehta-Shah, Peter Westervelt, Brad S. Kahl, Nancy L. Bartlett, John F. DiPersio
Journal: Blood (2020)
Progression signature underlies clonal evolution and dissemination of multiple myeloma
Authors: Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial
Journal: Blood (2020)
Mutated GM-CSF-Based CAR T-Cells Targeting CD116/CD131 Complexes Exhibit Enhanced Anti-Tumor Effects Against Acute Myeloid Leukemia
Authors: Shoji Saito, Aiko Hasegawa, Mika Nagai, Yoichi Inada, Hirokazu Morokawa, Ikumi Nakashima, Daisuke Morita, Yuichiro Ide, Kazuyuki Matsuda, Haruko Tashiro, Shigeki Yagyu, Miyuki Tanaka, Yozo Nakazawa
Journal: Blood (2020)
E-cigarettes for smokers trying to quit
Authors: Serena Tonstad
Journal: European Respiratory Journal (2020)

The letter by P.A. Katsaounou brings up major issues in the current somewhat "heated" discussion regarding the pros and cons of e-cigarettes as an aid to smoking cessation. The comments centre on the study by Hajek et al. [1], that found an almost 2:1 win for e-cigarettes compared to nicotine replacement therapy (NRT) for adult smokers attending the National Health Service Stop Smoking Services in the UK. Was the study flawed in the ways suggested by P.A. Katsaounou and, more importantly, is there any role for e-cigarettes in aiding smoking cessation? A more positive response to a previous correspondence regarding a study of e-cigarettes for quitting smoking <https://bit.ly/33UQAgr>
Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy
Authors: Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Susan DeWolf, Josel D Ruiz, Doris M Ponce, Brian C. Shaffer, Roni Tamari, James W. Young, Juliet Barker, Ann A. Jakubowski, Boglarka Gyurkocza, Alexander Chan, Wenbin Xiao, Jacob L Glass, Amber C. King, Sheng F Cai, Anthony Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Eytan M. Stein, Mikhail Roshal, Sergio Giralt, Miguel-Angel Perales, Christina Cho, Martin S. Tallman, Aaron D Goldberg
Journal: Blood (2020)
Wearable sensor data and self-reported symptoms for COVID-19 detection
Authors: Giorgio Quer, Jennifer M. Radin, Matteo Gadaleta, Katie Baca-Motes, Lauren Ariniello, Edward Ramos, Vik Kheterpal, Eric J. Topol, Steven R. Steinhubl
Journal: Nature Medicine (2020)

Traditional screening for COVID-19 typically includes survey questions about symptoms and travel history, as well as temperature measurements. Here, we explore whether personal sensor data collected over time may help identify subtle changes indicating an infection, such as in patients with COVID-19. We have developed a smartphone app that collects smartwatch and activity tracker data, as well as self-reported symptoms and diagnostic testing results, from individuals in the United States, and have assessed whether symptom and sensor data can differentiate COVID-19 positive versus negative cases in symptomatic individuals. We enrolled 30,529 participants between 25 March and 7 June 2020, of whom 3,811 reported symptoms. Of these symptomatic individuals, 54 reported testing positive and 279 negative for COVID-19. We found that a combination of symptom and sensor data resulted in an area under the curve (AUC) of 0.80 (interquartile range (IQR): 0.73–0.86) for discriminating between symptomatic individuals who were positive or negative for COVID-19, a performance that is significantly better (P < 0.01) than a model1 that considers symptoms alone (AUC = 0.71; IQR: 0.63–0.79). Such continuous, passively captured data may be complementary to virus testing, which is generally a one-off or infrequent sampling assay. A smartphone app that combines smartwatch and activity tracker data together with self-reported symptoms allows continuous monitoring of SARS-CoV-2 infection.
A ROR1 Bispecific T Cell Engager for the Treatment of Chronic Lymphocytic Leukaemia Demonstrates Enhanced Function Following Ibrutinib Treatment
Authors: Satyen Gohil, Solange Rosa Paredes-Moscosso, Micaela Harrasser, Mohamed El-Kholy, Emma Morris, Amit Nathwani, Marco Della Peruta
Journal: Blood (2017)
Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups
Authors: Daniel Rivera, Hagop M. Kantarjian, Gautam Borthakur, Marina Konopleva, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Koichi Takahashi, Elias Jabbour, Guillermo Montalban-Bravo, Musa Yilmaz, Sherry A. Pierce, Michael Andreeff, Kapil N. Bhalla, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood (2020)
Endovascular aortic repair for aorto-esophageal fistula in a young man: have all loose ends been tied?
Authors: Sundeep Lakhtakia, Zaheer Nabi, Sanjeev Kumar, Srinivas Ila, D. Nageshwar Reddy
Journal: Endoscopy (2020)

A 36-year-old man presented with a history of large-volume hematemesis. Clinical examination revealed severe pallor, hypotension, and feeble peripheral pulses. After initial resuscitation, an upper gastrointestinal (GI) endoscopy was performed, which revealed an ulcerated lesion at about 32 cm from the incisors ([Fig. 1]). An attempt was made to close the ulcer with endoclips but was unsuccessful ([Fig. 2]). Contrast-enhanced computed tomography (CT) revealed a large hematoma around the thoracic aorta, contrast outpouching, and expanding thrombus along the adjacent esophagus, suggesting the diagnosis of an aorto-esophageal fistula ([Fig. 3]). The aortic rent was closed using an 8 to 10-mm patent ductus arteriosus closure device, and a nasogastric tube was placed for feeding.
Abstract IA16: Cancer evolution, immune evasion and metastasis
Authors: Charles Swanton
Journal: Cancer Research (2020)

Abstract Increasing evidence supports complex subclonal relationships in solid tumours, manifested as intratumour heterogeneity. Parallel evolution of subclones, with distinct somatic events occurring in the same gene, signal transduction pathway or protein complex, suggests constraints to tumour evolution that might be therapeutically exploitable. Data from TRACERx, a longitudinal lung cancer evolution study will be presented. Drivers of tumour heterogeneity change during the disease course and contribute to the temporally distinct origins of lung cancer driver events. APOBEC driven mutagenesis appears to be enriched in subclones in multiple tumour types. Oncogene, tumour suppressor gene and drug induced DNA replication stress are found to drive APOBEC mutagenesis. Phylogenetic tracking detects minimal residual disease and clonal evolution of disease from primary to metastatic sites, presenting opportunities for drug development. On-going chromosomal instability, manifested as Mirrored Subclonal Allelic Imbalance (MSAI) is found to be a major driver of intratumour heterogeneity across cancer types, contributing to parallel evolution and selection. The finding of subclonal driver events, evidence of ongoing selection within subclones, combined with genome instability driving cell-to-cell variation is likely to limit the efficacy of targeted monotherapies, suggesting the need for new approaches to drug development and clinical trial design and integration of cancer immunotherapeutic approaches. Multiple adaptive mechanisms to neo-antigen evolution have been found in TRACERx that emphasise the role of cancer chromosomal instability driving immune evasion and HLA/MHC loss and loss of clonal neo-antigens as well as epigenetic repression of neo-antigens. The clonal neo-antigenic architecture may act as a tumour vulnerability, targeting multiple clonal neo-antigens present in each tumour to mitigate resistance and treatment failure. Citation Format: Charles Swanton. Cancer evolution, immune evasion and metastasis [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA16.
Totally laparoscopic plus one transthoracic port esophagogastrectomy for Siewert-type Ⅱ adenocarcinoma of esophagogastric junction.
Authors: Wei Wang, Wenjun Xiong, Yuling Xue, Jin Li, Haipeng Huang, Yansheng Zheng, Lijie Luo, Jin Wan
Journal: Journal of Clinical Oncology (2020)

e16568 Background: The incidence of Siewert type Ⅱ adenocarcinoma of esophagogastric junction (AEG) is increasing, especially in Asia, but laparoscopic surgery for type Ⅱ AEG is not widely accepted due to the technical challenges and unknown prognosis. To address this problem, we developed a novel technique of totally laparoscopic plus one transthoracic port esophagogastrectomy. Methods: From May 2017 to December 2019, 24 patients with advanced Siewert type Ⅱ AEG underwent the procedure. The surgical technique is that after completely abdominal lymphadenectomy and mobilization of the stomach laparoscopically, the left diaphragm was incised 5 to 7 cm, followed by one transthoracic port was inserted into the thoracic cavity through the left axillary frontline at the sixth to eighth intercostal spaces. Then lower mediastinal lymphadenectomy and transection of the lower esophagus were completed through the transthoracic supplementary port. An intrathoracic Roux-en-Y esophagojejunostomy was performed also through this port, which was finally used for thoracic drainage. Results: All procedures containing 5 proximal gastrectomies and 19 total gastrectomies were completed successfully without surgical morbidity and mortality. The median operative time was 344 (205 to 540) min. The time for reconstruction was 38 (25 to 60) min. The median blood loss was 100 (20 to 300) ml. The median tumor diameter was 3.8 (1.5 to 6.7) cm with a median esophagus invasion of 2.5 (0.6 to 4.5) cm. The median number of lymph nodes harvest was 37 (18 to 60). The median number of lower mediastinal lymph nodes was 5 (1 to 13) and its metastasis rate was 33.3%(8/24). The median time of first flatus was 4 (2 to 7) days. The median hospital stay was 11 (7 to 45) days. One patient developed a thoracic infection and one esophagojejunostomy leakage, both cured with thoracic drainage and antibiotic treatment. The median follow-up was 22(1-32). The DFS was 83.3% and OS was 91.7%. Conclusions: Our initial result suggested that this novel technique was safe and feasible for Siewert type Ⅱ AEG, associated with the advantages of complete lower mediastinal lymphadenectomy and easy intrathoracic Roux-en-Y esophagojejunostomy by using the transthoracic assisted port.
Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Authors: Benjamin Diamond, Kylee H Maclachlan, Andriy Derkach, Venkata Yellapantula, Even H Rustad, Malin Hultcrantz, Urvi A Shah, Jessica Hong, Heather J Landau, Christine Iacobuzio-Donahue, Elli Papaemmanuil, Shani I Irby, Laura Crowley, Michael Crane, Mayris Webber, David Goldfarb, Rachel Zeig-Owens, Orsi Giricz, Amit Verma, David Prezant, Ahmet Dogan, Sohrab P Shah, Yanming Zhang, Ola Landgren, Francesco Maura
Journal: Blood (2020)
Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma
Authors: JIA Wei, Min Xiao, Zekai Mao, Na Wang, Chunrui Li, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Yicheng Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang
Journal: Blood (2020)
Drug‐specific T‐cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat
Authors: Paul J. Thomson, Laila Kafu, Xiaoli Meng, Jan Snoeys, An De Bondt, Dries De Maeyer, Hans Wils, Laurent Leclercq, Petra Vinken, Dean J. Naisbitt
Journal: Allergy (2020)

Atabecestat is an orally administered BACE inhibitor developed to treat Alzheimer's disease. Elevations in hepatic enzymes were detected in a number of in trial patients, which resulted in termination of the drug development programme. Immunohistochemical characterization of liver tissue from an index case of atabecestat-mediated liver injury revealed an infiltration of T-lymphocytes in areas of hepatocellular damage. This coupled with the fact that liver injury had a delayed onset suggests that the adaptive immune system may be involved in the pathogenesis. The aim of this study was to generate and characterize atabecestat(metabolite)-responsive T-cell clones from patients with liver injury.Peripheral blood mononuclear cells were cultured with atabecestat and its metabolites (diaminothiazine [DIAT], N-acetyl DIAT & epoxide) and cloning was attempted in a number of patients. Atabecestat(metabolite)-responsive clones were analysed in terms of T-cell phenotype, function, pathways of T-cell activation and cross-reactivity with structurally related compounds.CD4+ T-cell clones activated with the DIAT metabolite were detected in 5 out of 8 patients (up to 4.5% cloning efficiency). Lower numbers of CD4+ and CD8+ clones displayed reactivity against atabecestat. Clones proliferated and secreted IFN-γ, IL-13 and cytolytic molecules following atabecestat or DIAT stimulation. Certain atabecestat and DIAT-responsive clones cross-reacted with N-acetyl DIAT; however, no cross-reactivity was observed between atabecestat and DIAT. CD4+ clones were activated through a direct, reversible compound-HLA class II interaction with no requirement for protein processing.The detection of atabecestat metabolite-responsive T-cell clones activated via a pharmacological interactions pathway in patients with liver injury is indicative of an immune-based mechanism for the observed hepatic enzyme elevations.
Preliminary Exploration of Ibrutinib Combined with Methotrexate, Ifosfamide, Liposomal Doxorubicin and Methylprednisolone in the Treatment of Relapsed/Refractory Primary CNS Lymphoma
Authors: Chen Yuedan, Xuefei Sun, Xueyan Bai, Qu Cui, Ruixian Xing, Yuanbo Liu
Journal: Blood (2020)
Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study
Authors: Teena Bhatla, Laura Hogan, Xinxin Xu, Lingyun Ji, Andrew J Carroll, Nyla A Heerema, Mary Shago, Lia Gore, James A. Whitlock, Stephen P Hunger, Mignon L. Loh, Patrick A. Brown
Journal: Blood (2020)
High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins
Authors: Muharrem Muftuoglu, Zoe Alaniz, Duncan Mak, Angelique J. Lin, Jared K. Burks, Bing Z Carter, Michael Andreeff
Journal: Blood (2020)
Abstract 511: Transcriptomic Analysis of End-stage Human Heart Failure Highlights Strong Interaction Effect Between Race and Diabetes
Authors: Luke A Potter, Mark E Pepin, Chae-myeong Ha, Sayan Bakshi, Adam R Wende
Journal: Circulation Research (2020)

African Americans (AA) have an elevated risk for cardiovascular diseases compared to Caucasian Americans (CA), including heart failure (HF). Type 2 diabetes (T2D) is a major risk factor for HF that also disproportionately affects AA. These health disparities and others reduce life expectancy ~3.5 y for AA compared to CA. While prior studies have explored the connection between diabetes and heart failure, the current understanding of HF pathogenesis is based almost exclusively from studies of CA, whereas those considering race have been either epidemiologic or narrow in focus. The purpose of this study was to examine things from a different angle through the use of genome-wide RNA-sequencing to uncover how diabetes differentially or similarly affects end-stage heart failure in AA vs CA. To accomplish this, human biopsy samples were obtained from 32 age and diabetes status (T2D or non-diabetic (ND)) matched male patients undergoing left ventricle assist device surgeries (n = 8: CA-ND, CA-T2D, AA-ND, AA-T2D). Differential expression analysis was then performed using generalized linear modeling to control for clinical covariates including hypertension and coronary artery disease. Results of T2D vs ND in AA patients showed a greater number of differentially expressed genes (DEGs, P &lt; 0.05,
SAT0182 Assessment of bone metabolism in patients with chronic connective tissue diseases
Authors: I Korczowska, P Leszczynski, P Hrycaj, JK Lacki
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> The aim of our recent study was to evaluate bone metabolism in rheumatoid arthritis (RA) and systemic lupus erythematosus patients (SLE). <h3>Methods</h3> 306 women (90 RA, 38 SLE patients and 178 healthy volunteers) were involved in the study. All SLE and 44 RA patients were on chronic glucocorticosteroids theraphy (GCS). Average age was: 46.4 ± 12.8 yrs, 52.0 ± 12.0 yrs in SLE group and the control (respectively). Disease duration and duration of GCS therapy in SLE patients was: 108 ± 82 months. Total dose of GCS was the highest in SLE pts (25.3 ± 28.19 g). Patients with RA were divided into two groups: treated with GCS (average age: 52.5 ± 12.4 yrs, disease duration and duration of GCS therapy: 122 ± 102 months, total dose of GCS: 7.4 ± 8.3 g): and who were not treated with GCS (average age: 54.3 ± 9.7 yrs, disease duration: 134 ± 120 months). In all patients the following markers of bone metabolism were measured: osteocalcin, procolagen C, alkaline phosphatase-bone fraction, carboxyterminal telopeptides of type I collagen (CTX), procollagen type I carboxyterminal propeptide (PICP), deoxypyridynoline. The disease activity was assessed by measuring serum levels of proinflammatory cytokines (IL-1a, IL-6, TNF-alpha, GM-CSF) and acute phase markers (ESR, CRP, AGP, AGP-RC, ACT). <h3>Results</h3> Concentration of biochemical markers of osteoporosis suggesting increased bone metabolism in RA patients indicates significantly higher bone loss in this group than in SLE patients in spite of the highest dosage of GCS. There was no significantly differences between bone turnover in RA patients treated and not treated with GCS. <h3>Conclusion</h3> The serum levels of proinflammatory cytokines and acute phase markers confirm the highest stage of the disease activity in RA patients.
Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
Authors: Farah Ashraf, Anita Mazloom, Neil Nimkar, Nisha Patel, Amardeep Kalsi, Angelica Singh, Sonal Paul, Nivetha Vishnuvardhan, Abeer Ashfaq, Soeb Usta, Rich Kodama, Chathula Kumarasinghe, Peter Gregos, Jeremy Weingarten, Uqba Khan, Eshan Patel
Journal: Blood (2020)
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
Authors: Yaling Tang, Hetal Shah, Carlos Roberto Bueno Junior, Xiuqin Sun, Joanna Mitri, Maria Sambataro, Luisa Sambado, Hertzel C. Gerstein, Vivian Fonseca, Alessandro Doria, Rodica Pop-Busui
Journal: Diabetes Care (2020)

OBJECTIVE The effects of preventive interventions on cardiovascular autonomic neuropathy (CAN) remain unclear. We examined the effect of intensively treating traditional risk factors for CAN, including hyperglycemia, hypertension, and dyslipidemia, in individuals with type 2 diabetes (T2D) and high cardiovascular risk participating in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS CAN was defined as heart rate variability indices below the fifth percentile of the normal distribution. Of 10,251 ACCORD participants, 71% (n = 7,275) had a CAN evaluation at study entry and at least once after randomization. The effects of intensive interventions on CAN were analyzed among these subjects through generalized linear mixed models. RESULTS As compared with standard intervention, intensive glucose treatment reduced CAN risk by 16% (odds ratio [OR] 0.84, 95% CI 0.75–0.94, P = 0.003)—an effect driven by individuals without cardiovascular disease (CVD) at baseline (OR 0.73, 95% CI 0.63–0.85, P &amp;lt; 0.0001) rather than those with CVD (OR 1.10, 95% CI 0.91–1.34, P = 0.34) (Pinteraction = 0.001). Intensive blood pressure (BP) intervention decreased CAN risk by 25% (OR 0.75, 95% CI 0.63–0.89, P = 0.001), especially in patients ≥65 years old (OR 0.66, 95% CI 0.49–0.88, P = 0.005) (Pinteraction = 0.05). Fenofibrate did not have a significant effect on CAN (OR 0.91, 95% CI 0.78–1.07, P = 0.26). CONCLUSIONS These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.